Siga Technologies, Inc.
A pharmaceutical company that makes antiviral drugs for serious infectious diseases and biothreats, best known for TPOXX (tecovirimat), the first drug approved in the U.S. to treat smallpox and stockpiled by governments against bioterror threats. Founded in 1995 by Steven Oliveira and based in New York City, it works with U.S. agencies like BARDA on medical countermeasures. Fun fact: since smallpox was eradicated, TPOXX won approval under the FDA's "Animal Rule," which allows a drug to be approved on animal studies when human trials aren't possible.
Granted 10.63M
Bought 1.40M
Bought 3.85M
Bought 288.5K
Sold 4.85M
Granted 1.92M · Bought 25.5K · Sold 131.5K
Granted 882.4K · Bought 25.0K
Granted 363.5K · Sold 56.3K
Granted 196.7K · Bought 90.0K
Granted 443.9K · Bought 5.0K · Sold 7.5K
Granted 278.4K · Bought 15.0K
Granted 915.3K · Sold 565.0K
Granted 129.2K · Bought 180.0K · Sold 40.0K
Granted 256.1K
Granted 149.5K · Bought 20.8K · Sold 29.0K
Granted 127.3K
Granted 233.2K · Sold 115.0K
Granted 120.4K
Granted 105.4K
Granted 105.4K
Granted 30.0K · Bought 50.0K
Granted 75.7K · Bought 1.5K
Granted 82.8K
Granted 105.4K
Granted 75.0K
Granted 67.9K
Granted 92.0K
Granted 95.0K
Granted 52.8K · Bought 2.5K
Granted 30.0K · Bought 2.0K
Granted 25.0K · Bought 1.0K
Granted 24.1K
Sold 4.85M
Granted 24.7K
Granted 24.7K
Granted 40.0K · Sold 157.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| MacAndrews & Forbes Inc. +2 co-filersDirector, 10% owner · 2 transactions | — | 24.16Mas of Nov 2016 | 10.63M | — | — |
| MacAndrews & Forbes Holdings Inc. +2 co-filersDirector, 10% owner · 7 transactions | — | 13.51Mas of Nov 2014 | — | 1.40M | — |
| MacAndrews & Forbes Holdings Inc. +3 co-filersDirector, 10% owner · 10 transactions | — | 13.20Mas of Jan 2011 | — | 3.85M | — |
| MacAndrews & Forbes Holdings Inc. +2 co-filers10% owner · 1 transaction | — | 7.62Mas of Dec 2007 | — | 288.5K | — |
| Transtech Pharma Inc10% owner · 4 transactions | — | 4.32Mas of Sep 2009 | — | — | 4.85M |
| Rose Eric A MDDirector · 50 transactions | — | 1.07Mas of Jun 2021 | 1.92M | 25.5K | 131.5K |
| Gomez Phillip Louis IIIChief Executive Officer, Director · 6 transactions | — | 475.8Kas of Dec 2019 | 882.4K | 25.0K | — |
| Constance Thomas EDirector · 16 transactions | — | 327.8Kas of Jun 2021 | 363.5K | — | 56.3K |
| Savas Paul GDirector · 22 transactions | — | 307.8Kas of May 2020 | 196.7K | 90.0K | — |
| Luckshire Daniel JExecutive VP & CFO · 40 transactions | — | 280.5K | 443.9K | 5.0K | 7.5K |
| Marshall Joseph W IIIDirector · 25 transactions | — | 246.5K | 278.4K | 15.0K | — |
| Hruby Dennis EEVP & Chief Scientific Officer · 56 transactions | — | 202.5K | 915.3K | — | 565.0K |
| Slovin BruceDirector · 39 transactions | — | 194.2Kas of May 2017 | 129.2K | 180.0K | 40.0K |
| Nguyen DiemChief Executive Officer, Director · 8 transactions | — | 185.8K | 256.1K | — | — |
| Bayer Michael JDirector · 15 transactions | — | 132.2Kas of Jun 2019 | 149.5K | 20.8K | 29.0K |
| Kindler Jeffrey BDirector · 8 transactions | — | 127.3Kas of May 2020 | 127.3K | — | — |
| Antal JamesDirector · 20 transactions | — | 116.9Kas of Jun 2022 | 233.2K | — | 115.0K |
| Durnan Jaymie ADirector · 11 transactions | — | 88.8K | 120.4K | — | — |
| Nemirovsky JulianDirector · 10 transactions | — | 81.0K | 105.4K | — | — |
| Phillips Holly L.Director · 10 transactions | — | 81.0K | 105.4K | — | — |
| Bevins William CDirector · 3 transactions | — | 80.0Kas of May 2014 | 30.0K | 50.0K | — |
| Stern Andrew LDirector · 8 transactions | — | 77.9Kas of May 2017 | 75.7K | 1.5K | — |
| Plansky Michael C.Director · 6 transactions | — | 76.0Kas of Jun 2022 | 82.8K | — | — |
| Nabel Gary J.Director · 10 transactions | — | 73.8K | 105.4K | — | — |
| Haynes William J IIExecutive VP & General Counsel · 10 transactions | — | 63.9Kas of Sep 2015 | 75.0K | — | — |
| Ford Harold Eugene Jr.Director · 6 transactions | — | 54.8K | 67.9K | — | — |
| Miller Larry R.General Counsel · 10 transactions | — | 51.9K | 92.0K | — | — |
| Abrams Robin ElizabethGeneral Counsel and CAO · 8 transactions | — | 49.8Kas of Jul 2021 | 95.0K | — | — |
| Kane JulieDirector · 5 transactions | — | 48.5Kas of Jun 2022 | 52.8K | 2.5K | — |
| Townsend Frances FDirector · 4 transactions | — | 32.0Kas of May 2014 | 30.0K | 2.0K | — |
| Fasman Steven LDirector · 2 transactions | — | 27.0Kas of Mar 2011 | 25.0K | 1.0K | — |
| Oz Mehmet C MDDirector · 1 transaction | — | 25.0Kas of May 2008 | — | — | — |
| Keane John MDirector · 2 transactions | — | 24.1K | 24.1K | — | — |
| Mjalli Adnan M MDirector, 10% owner · 4 transactions | — | 21.0Kas of Sep 2009 | — | — | 4.85M |
| Knisely Evan A.Director · 2 transactions | — | 17.3Kas of Jun 2024 | 24.7K | — | — |
| Varma JayEVP & Chief Medical Officer, Director · 2 transactions | — | 17.3Kas of Jun 2024 | 24.7K | — | — |
| Weiner Michael MDDirector · 28 transactions | — | 15.0Kas of May 2014 | 40.0K | — | 157.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -4.84M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.